Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Prostate Cancer

Free Subscription Articles published in Oncogene Retrieve available abstracts of 75 articles: HTML format

Single Articles

September 2023
1. ADVANI R, Luzzi S, Scott E, Dalgliesh C, et al
   Epithelial specific splicing regulator proteins as emerging oncogenes in aggressive prostate cancer.
   Oncogene. 2023 Sep 26. doi: 10.1038/s41388-023-02838.
   PubMed     Abstract available
   
   
   August 2023
2. BUNAY J, Kossai M, Damon-Soubeyrant C, De Haze A, et al
   Persistent organic pollutants promote aggressiveness in prostate cancer.
   Oncogene. 2023 Aug 17. doi: 10.1038/s41388-023-02788.
   PubMed     Abstract available
   
   
   
3. WU T, Zhang Y, Han Q, Lu X, et al
   Klotho-beta attenuates Rab8a-mediated exosome regulation and promotes prostate cancer progression.
   Oncogene. 2023 Aug 15. doi: 10.1038/s41388-023-02807.
   PubMed     Abstract available
   
   
   July 2023
4. BUSKIN A, Scott E, Nelson R, Gaughan L, et al
   Engineering prostate cancer in vitro: what does it take?
   Oncogene. 2023 Jul 12. doi: 10.1038/s41388-023-02776.
   PubMed     Abstract available
   
   
   
5. ZHOU Z, Jia D, Kwon O, Li S, et al
   Androgen-regulated stromal complement component 7 (C7) suppresses prostate cancer growth.
   Oncogene. 2023 Jul 3. doi: 10.1038/s41388-023-02759.
   PubMed     Abstract available
   
   
   June 2023
6. VLAJIC K, Pennington Kluger H, Bie W, Merrill BJ, et al
   Appearance of tuft cells during prostate cancer progression.
   Oncogene. 2023 Jun 29. doi: 10.1038/s41388-023-02743.
   PubMed     Abstract available
   
   
   
7. BLATT EB, Parra K, Neeb A, Buroni L, et al
   Critical role of antioxidant programs in enzalutamide-resistant prostate cancer.
   Oncogene. 2023 Jun 24. doi: 10.1038/s41388-023-02756.
   PubMed     Abstract available
   
   
   May 2023
8. LIN Z, Agarwal S, Tan S, Shi H, et al
   Palmitoyl acyltransferase ZDHHC7 inhibits androgen receptor and suppresses prostate cancer.
   Oncogene. 2023 May 17. doi: 10.1038/s41388-023-02718.
   PubMed     Abstract available
   
   
   April 2023
9. LI Z, Jiao X, Robertson AG, Di Sante G, et al
   The DACH1 gene is frequently deleted in prostate cancer, restrains prostatic intraepithelial neoplasia, decreases DNA damage repair, and predicts therapy responses.
   Oncogene. 2023 Apr 24. doi: 10.1038/s41388-023-02668.
   PubMed     Abstract available
   
   
   
10. KIM H, Barua A, Huang L, Zhou T, et al
    The cancer testis antigen TDRD1 regulates prostate cancer proliferation by associating with the snRNP biogenesis machinery.
    Oncogene. 2023 Apr 12. doi: 10.1038/s41388-023-02690.
    PubMed     Abstract available
    
    
    
11. CAMERON S, Deblois G, Hawley JR, Qamra A, et al
    Chronic hypoxia favours adoption to a castration-resistant cell state in prostate cancer.
    Oncogene. 2023 Apr 5. doi: 10.1038/s41388-023-02680.
    PubMed     Abstract available
    
    
    March 2023
12. YENDE AS, Williams EC, Pletcher A, Helfand A, et al
    TRIM28 promotes luminal cell plasticity in a mouse model of prostate cancer.
    Oncogene. 2023 Mar 8. doi: 10.1038/s41388-023-02655.
    PubMed     Abstract available
    
    
    
13. NIKESITCH N, Beraldi E, Zhang F, Adomat H, et al
    Chaperone-mediated autophagy promotes PCa survival during ARPI through selective proteome remodeling.
    Oncogene. 2023;42:748-758.
    PubMed     Abstract available
    
    
    
14. DING Y, Chen J, Li S, Wren JD, et al
    EWI2 and its relatives in Tetraspanin-enriched membrane domains regulate malignancy.
    Oncogene. 2023;42:861-868.
    PubMed     Abstract available
    
    
    February 2023
15. GRITSINA G, Yu J
    CXCR7 as a novel therapeutic target for advanced prostate cancer.
    Oncogene. 2023 Feb 9. doi: 10.1038/s41388-023-02597.
    PubMed     Abstract available
    
    
    
16. SCOTT E, Hodgson K, Calle B, Turner H, et al
    Upregulation of GALNT7 in prostate cancer modifies O-glycosylation and promotes tumour growth.
    Oncogene. 2023 Feb 1. doi: 10.1038/s41388-023-02604.
    PubMed     Abstract available
    
    
    January 2023
17. YANG JC, Xu P, Ning S, Wasielewski LJ, et al
    Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer.
    Oncogene. 2023 Jan 3. doi: 10.1038/s41388-022-02566.
    PubMed     Abstract available
    
    
    December 2022
18. FAN L, Gong Y, He Y, Gao WQ, et al
    TRIM59 is suppressed by androgen receptor and acts to promote lineage plasticity and treatment-induced neuroendocrine differentiation in prostate cancer.
    Oncogene. 2022 Dec 21. doi: 10.1038/s41388-022-02498.
    PubMed     Abstract available
    
    
    October 2022
19. KIKUNO N, Shiina H, Urakami S, Kawamoto K, et al
    Retraction Note: Knockdown of astrocyte-elevated gene-1 inhibits prostate cancer progression through upregulation of FOXO3a activity.
    Oncogene. 2022 Oct 19. pii: 10.1038/s41388-022-02501.
    PubMed    
    
    
    
20. GUO Y, He J, Zhang H, Chen R, et al
    Linear ubiquitination of PTEN impairs its function to promote prostate cancer progression.
    Oncogene. 2022 Oct 3. pii: 10.1038/s41388-022-02485.
    PubMed     Abstract available
    
    
    
21. TAN Q, Liu Z, Gao X, Wang Y, et al
    Celastrol recruits UBE3A to recognize and degrade the DNA binding domain of steroid receptors.
    Oncogene. 2022;41:4754-4767.
    PubMed     Abstract available
    
    
    September 2022
22. AHN S, Saha A, Clark R, Kolonin MG, et al
    CXCR4 and CXCR7 signaling promotes tumor progression and obesity-associated epithelial-mesenchymal transition in prostate cancer cells.
    Oncogene. 2022 Sep 10. pii: 10.1038/s41388-022-02466.
    PubMed     Abstract available
    
    
    
23. WANG C, Li W, Hu Q, Feng N, et al
    Transgenic construction and functional miRNA analysis identify the role of miR-7 in prostate cancer suppression.
    Oncogene. 2022 Sep 10. pii: 10.1038/s41388-022-02461.
    PubMed     Abstract available
    
    
    
24. WANG X, Brea L, Lu X, Gritsina G, et al
    FOXA1 inhibits hypoxia programs through transcriptional repression of HIF1A.
    Oncogene. 2022;41:4259-4270.
    PubMed     Abstract available
    
    
    
25. LI C, Liu J, He D, Mao F, et al
    GSTM2 is a key molecular determinant of resistance to SG-ARIs.
    Oncogene. 2022;41:4498-4511.
    PubMed     Abstract available
    
    
    August 2022
26. WANG J, Li J, Yin L, Pu T, et al
    Neuropilin-2 promotes lineage plasticity and progression to neuroendocrine prostate cancer.
    Oncogene. 2022 Aug 19. pii: 10.1038/s41388-022-02437.
    PubMed     Abstract available
    
    
    
27. MOUILLET-RICHARD S, Martin-Lanneree S, Le Corre D, Hirsch TZ, et al
    A proof of concept for targeting the PrP(C) - Amyloid beta peptide interaction in basal prostate cancer and mesenchymal colon cancer.
    Oncogene. 2022 Aug 12. pii: 10.1038/s41388-022-02430.
    PubMed     Abstract available
    
    
    
28. IPSEN MB, Sorensen EMG, Thomsen EA, Weiss S, et al
    A genome-wide CRISPR-Cas9 knockout screen identifies novel PARP inhibitor resistance genes in prostate cancer.
    Oncogene. 2022 Aug 6. pii: 10.1038/s41388-022-02427.
    PubMed     Abstract available
    
    
    July 2022
29. LI Z, Li B, Yu H, Wang P, et al
    DNMT1-mediated epigenetic silencing of TRAF6 promotes prostate cancer tumorigenesis and metastasis by enhancing EZH2 stability.
    Oncogene. 2022 Jul 8. pii: 10.1038/s41388-022-02404.
    PubMed     Abstract available
    
    
    
30. WENTA T, Schmidt A, Zhang Q, Devarajan R, et al
    Disassembly of alpha6beta4-mediated hemidesmosomal adhesions promotes tumorigenesis in PTEN-negative prostate cancer by targeting plectin to focal adhesions.
    Oncogene. 2022 Jul 1. pii: 10.1038/s41388-022-02389.
    PubMed     Abstract available
    
    
    June 2022
31. DUTTA S, Polavaram NS, Islam R, Bhattacharya S, et al
    Neuropilin-2 regulates androgen-receptor transcriptional activity in advanced prostate cancer.
    Oncogene. 2022 Jun 27. pii: 10.1038/s41388-022-02382.
    PubMed     Abstract available
    
    
    
32. SUN F, Wang X, Hu J, Liu J, et al
    RUVBL1 promotes enzalutamide resistance of prostate tumors through the PLXNA1-CRAF-MAPK pathway.
    Oncogene. 2022;41:3239-3250.
    PubMed     Abstract available
    
    
    May 2022
33. KHANDRIKA L, Lieberman R, Koul S, Kumar B, et al
    Retraction Note: Hypoxia-associated p38 mitogen-activated protein kinase-mediated androgen receptor activation and increased HIF-1alpha levels contribute to emergence of an aggressive phenotype in prostate cancer.
    Oncogene. 2022 May 19. pii: 10.1038/s41388-022-02357.
    PubMed    
    
    
    
34. CONSTANTIN TA, Greenland KK, Varela-Carver A, Bevan CL, et al
    Transcription associated cyclin-dependent kinases as therapeutic targets for prostate cancer.
    Oncogene. 2022 May 14. pii: 10.1038/s41388-022-02347.
    PubMed     Abstract available
    
    
    
35. EHSANI M, Bartsch S, Rasa SMM, Dittmann J, et al
    The natural compound atraric acid suppresses androgen-regulated neo-angiogenesis of castration-resistant prostate cancer through angiopoietin 2.
    Oncogene. 2022 May 5. pii: 10.1038/s41388-022-02333.
    PubMed     Abstract available
    
    
    
36. JI D, Shang G, Wei E, Jia Y, et al
    Targeting CDCP1 gene transcription coactivated by BRD4 and CBP/p300 in castration-resistant prostate cancer.
    Oncogene. 2022 May 5. pii: 10.1038/s41388-022-02327.
    PubMed     Abstract available
    
    
    
37. ZHANG Y, Xu Z, Wen W, Liu Z, et al
    The microRNA-3622 family at the 8p21 locus exerts oncogenic effects by regulating the p53-downstream gene network in prostate cancer progression.
    Oncogene. 2022 May 2. pii: 10.1038/s41388-022-02289.
    PubMed     Abstract available
    
    
    April 2022
38. GAO P, Hao JL, Xie QW, Han GQ, et al
    PELO facilitates PLK1-induced the ubiquitination and degradation of Smad4 and promotes the progression of prostate cancer.
    Oncogene. 2022 Apr 18. pii: 10.1038/s41388-022-02316.
    PubMed     Abstract available
    
    
    
39. LIN HY, Ko CJ, Lo TY, Wu SR, et al
    Matriptase-2/NR4A3 axis switches TGF-beta action toward suppression of prostate cancer cell invasion, tumor growth, and metastasis.
    Oncogene. 2022 Apr 13. pii: 10.1038/s41388-022-02303.
    PubMed     Abstract available
    
    
    
40. COPELLO VA, Burnstein KL
    The kinesin KIF20A promotes progression to castration-resistant prostate cancer through autocrine activation of the androgen receptor.
    Oncogene. 2022 Apr 13. pii: 10.1038/s41388-022-02307.
    PubMed     Abstract available
    
    
    
41. BRAMHECHA YM, Guerard KP, Audet-Walsh E, Rouzbeh S, et al
    Fatty acid oxidation enzyme Delta3, Delta2-enoyl-CoA isomerase 1 (ECI1) drives aggressive tumor phenotype and predicts poor clinical outcome in prostate cancer patients.
    Oncogene. 2022 Apr 11. pii: 10.1038/s41388-022-02276.
    PubMed     Abstract available
    
    
    March 2022
42. WANG C, Leavenworth J, Zhang C, Liu Z, et al
    Epigenetic regulation of EIF4A1 through DNA methylation and an oncogenic role of eIF4A1 through BRD2 signaling in prostate cancer.
    Oncogene. 2022 Mar 31. pii: 10.1038/s41388-022-02272.
    PubMed     Abstract available
    
    
    
43. WANG L, Wang J, Yin X, Guan X, et al
    GIPC2 interacts with Fzd7 to promote prostate cancer metastasis by activating WNT signaling.
    Oncogene. 2022 Mar 28. pii: 10.1038/s41388-022-02255.
    PubMed     Abstract available
    
    
    February 2022
44. DE WET L, Williams A, Gillard M, Kregel S, et al
    Correction to: SOX2 mediates metabolic reprogramming of prostate cancer cells.
    Oncogene. 2022 Feb 10. pii: 10.1038/s41388-022-02228.
    PubMed    
    
    
    January 2022
45. YI Y, Li Y, Li C, Wu L, et al
    Methylation-dependent and -independent roles of EZH2 synergize in CDCA8 activation in prostate cancer.
    Oncogene. 2022 Jan 29. pii: 10.1038/s41388-022-02208.
    PubMed     Abstract available
    
    
    
46. MELNYK JE, Steri V, Nguyen HG, Hwang YC, et al
    Targeting a splicing-mediated drug resistance mechanism in prostate cancer by inhibiting transcriptional regulation by PKCbeta1.
    Oncogene. 2022 Jan 27. pii: 10.1038/s41388-022-02179.
    PubMed     Abstract available
    
    
    
47. DE WET L, Williams A, Gillard M, Kregel S, et al
    SOX2 mediates metabolic reprogramming of prostate cancer cells.
    Oncogene. 2022 Jan 24. pii: 10.1038/s41388-021-02157.
    PubMed     Abstract available
    
    
    
48. XU L, Zhao B, Butler W, Xu H, et al
    Targeting glutamine metabolism network for the treatment of therapy-resistant prostate cancer.
    Oncogene. 2022 Jan 20. pii: 10.1038/s41388-021-02155.
    PubMed     Abstract available
    
    
    
49. CANNISTRACI A, Hascoet P, Ali A, Mundra P, et al
    MiR-378a inhibits glucose metabolism by suppressing GLUT1 in prostate cancer.
    Oncogene. 2022 Jan 17. pii: 10.1038/s41388-022-02178.
    PubMed     Abstract available
    
    
    
50. HAN W, Liu M, Han D, Li M, et al
    RB1 loss in castration-resistant prostate cancer confers vulnerability to LSD1 inhibition.
    Oncogene. 2022 Jan 3. pii: 10.1038/s41388-021-02135.
    PubMed     Abstract available
    
    
    
51. MCCANN JJ, Vasilevskaya IA, McNair C, Gallagher P, et al
    Mutant p53 elicits context-dependent pro-tumorigenic phenotypes.
    Oncogene. 2022;41:444-458.
    PubMed     Abstract available
    
    
    
52. ZHANG B, Zhang M, Yang Y, Li Q, et al
    Targeting KDM4A-AS1 represses AR/AR-Vs deubiquitination and enhances enzalutamide response in CRPC.
    Oncogene. 2022;41:387-399.
    PubMed     Abstract available
    
    
    December 2021
53. MIRZAKHANI K, Kallenbach J, Rasa SMM, Ribaudo F, et al
    Correction to: The androgen receptor-lncRNASAT1-AKT-p15 axis mediates androgen-induced cellular senescence in prostate cancer cells.
    Oncogene. 2021 Dec 20. pii: 10.1038/s41388-021-02125.
    PubMed    
    
    
    November 2021
54. LEE YC, Lin SC, Yu G, Zhu M, et al
    Prostate tumor-induced stromal reprogramming generates Tenascin C that promotes prostate cancer metastasis through YAP/TAZ inhibition.
    Oncogene. 2021 Nov 29. pii: 10.1038/s41388-021-02131.
    PubMed     Abstract available
    
    
    
55. MAZZU YZ, Liao YR, Nandakumar S, Jehane LE, et al
    Prognostic and therapeutic significance of COP9 signalosome subunit CSN5 in prostate cancer.
    Oncogene. 2021 Nov 20. pii: 10.1038/s41388-021-02118.
    PubMed     Abstract available
    
    
    October 2021
56. CHERIF C, Nguyen DT, Paris C, Le TK, et al
    Menin inhibition suppresses castration-resistant prostate cancer and enhances chemosensitivity.
    Oncogene. 2021 Oct 28. pii: 10.1038/s41388-021-02039.
    PubMed     Abstract available
    
    
    
57. MIRZAKHANI K, Kallenbach J, Rasa SMM, Ribaudo F, et al
    The androgen receptor-lncRNASAT1-AKT-p15 axis mediates androgen-induced cellular senescence in prostate cancer cells.
    Oncogene. 2021 Oct 19. pii: 10.1038/s41388-021-02060.
    PubMed     Abstract available
    
    
    
58. HU L, Chen X, Narwade N, Lim MGL, et al
    Single-cell analysis reveals androgen receptor regulates the ER-to-Golgi trafficking pathway with CREB3L2 to drive prostate cancer progression.
    Oncogene. 2021 Oct 5. pii: 10.1038/s41388-021-02026.
    PubMed     Abstract available
    
    
    September 2021
59. LABANCA E, Bizzotto J, Sanchis P, Anselmino N, et al
    Prostate cancer castrate resistant progression usage of non-canonical androgen receptor signaling and ketone body fuel.
    Oncogene. 2021 Sep 28. pii: 10.1038/s41388-021-02008.
    PubMed     Abstract available
    
    
    
60. ZHU M, Peng R, Liang X, Lan Z, et al
    P4HA2-induced prolyl hydroxylation suppresses YAP1-mediated prostate cancer cell migration, invasion, and metastasis.
    Oncogene. 2021 Sep 1. pii: 10.1038/s41388-021-02000.
    PubMed     Abstract available
    
    
    August 2021
61. PARK SH, Fong KW, Mong E, Martin MC, et al
    Going beyond Polycomb: EZH2 functions in prostate cancer.
    Oncogene. 2021 Aug 4. pii: 10.1038/s41388-021-01982.
    PubMed     Abstract available
    
    
    July 2021
62. LIU C, Armstrong CM, Ning S, Yang JC, et al
    ARVib suppresses growth of advanced prostate cancer via inhibition of androgen receptor signaling.
    Oncogene. 2021 Jul 16. pii: 10.1038/s41388-021-01914.
    PubMed     Abstract available
    
    
    June 2021
63. HAGIWARA M, Fushimi A, Yamashita N, Bhattacharya A, et al
    MUC1-C activates the PBAF chromatin remodeling complex in integrating redox balance with progression of human prostate cancer stem cells.
    Oncogene. 2021 Jun 23. pii: 10.1038/s41388-021-01899.
    PubMed     Abstract available
    
    
    
64. LAUNONEN KM, Paakinaho V, Sigismondo G, Malinen M, et al
    Chromatin-directed proteomics-identified network of endogenous androgen receptor in prostate cancer cells.
    Oncogene. 2021 Jun 14. pii: 10.1038/s41388-021-01887.
    PubMed     Abstract available
    
    
    
65. PAN T, Lin SC, Lee YC, Yu G, et al
    Statins reduce castration-induced bone marrow adiposity and prostate cancer progression in bone.
    Oncogene. 2021 Jun 14. pii: 10.1038/s41388-021-01874.
    PubMed     Abstract available
    
    
    
66. LIAO Y, Liu Y, Shao Z, Xia X, et al
    A new role of GRP75-USP1-SIX1 protein complex in driving prostate cancer progression and castration resistance.
    Oncogene. 2021 Jun 2. pii: 10.1038/s41388-021-01851.
    PubMed     Abstract available
    
    
    May 2021
67. LEE HC, Ou CH, Huang YC, Hou PC, et al
    Correction: YAP1 overexpression contributes to the development of enzalutamide resistance by induction of cancer stemness and lipid metabolism in prostate cancer.
    Oncogene. 2021 May 19. pii: 10.1038/s41388-021-01836.
    PubMed    
    
    
    
68. CRONIN R, Brooke GN, Prischi F
    The role of the p90 ribosomal S6 kinase family in prostate cancer progression and therapy resistance.
    Oncogene. 2021 May 10. pii: 10.1038/s41388-021-01810.
    PubMed     Abstract available
    
    
    
69. ZHU Y, Dalrymple SL, Coleman I, Zheng SL, et al
    Correction: Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors.
    Oncogene. 2021 May 6. pii: 10.1038/s41388-021-01805.
    PubMed    
    
    
    April 2021
70. WATSON MJ, Berger PL, Banerjee K, Frank SB, et al
    Aberrant CREB1 activation in prostate cancer disrupts normal prostate luminal cell differentiation.
    Oncogene. 2021 Apr 12. pii: 10.1038/s41388-021-01772.
    PubMed     Abstract available
    
    
    
71. PUHR M, Eigentler A, Handle F, Hackl H, et al
    Targeting the glucocorticoid receptor signature gene Mono Amine Oxidase-A enhances the efficacy of chemo- and anti-androgen therapy in advanced prostate cancer.
    Oncogene. 2021 Apr 1. pii: 10.1038/s41388-021-01754.
    PubMed     Abstract available
    
    
    
72. PURAYIL HT, Zhang Y, Black JB, Gharaibeh R, et al
    Nuclear betaArrestin1 regulates androgen receptor function in castration resistant prostate cancer.
    Oncogene. 2021;40:2610-2620.
    PubMed     Abstract available
    
    
    
73. ZHOU J, Wang Y, Wu D, Wang S, et al
    Orphan nuclear receptors as regulators of intratumoral androgen biosynthesis in castration-resistant prostate cancer.
    Oncogene. 2021;40:2625-2634.
    PubMed     Abstract available
    
    
    February 2021
74. LIU PI, Chang AC, Lai JL, Lin TH, et al
    Melatonin interrupts osteoclast functioning and suppresses tumor-secreted RANKL expression: implications for bone metastases.
    Oncogene. 2021;40:1503-1515.
    PubMed     Abstract available
    
    
    January 2021
75. KWON OJ, Zhang L, Jia D, Xin L, et al
    Sox2 is necessary for androgen ablation-induced neuroendocrine differentiation from Pten null Sca-1(+) prostate luminal cells.
    Oncogene. 2021;40:203-214.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: